In the Spotlight...
Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity
Non-viral precision T cell receptor replacement for personalized cell therapy
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Previous Digests
SITC Annual Meeting 2022
November 23, 2022
This week’s extensive special feature covers select talks from the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and virtually. We are proud to recognize Takeda for sponsorship of our coverage for this...
Targeting the sialoglycan-Siglec axis for cancer immunotherapy
November 16, 2022
In cancer, upregulation of sialic acid-containing glycans (hypersialylation) is a feature that has been shown to drive disease progression and immune escape through engagement with Siglec receptors and inhibition of tumor-infiltrating immune cells. In previous work, Stanczak et al...
Not all routes lead to Rome: administration route affects vaccine responses
November 9, 2022
Since cytolytic T cells are critical to cancer immunotherapy, therapeutic cancer vaccines, which can induce such T cells, can be an important component of immunotherapy. However, current vaccine approaches to improve the magnitude of the immune response have traditionally...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
Donate to support researchersAbout ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Lespinasse-Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Samuel (Sandy) Goldman
Paula Hochman
Shishir Pant
Elaine Yee Lin Chung
Nathan Suek
Margot O'Toole
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
